Evidence map›Paper›PMID 41811893›Full record

ArticleJournal of immunology research2026

Intermittent Tacrolimus Treatment Delays CD8+ Tumor-Infiltrating Lymphocyte Exhaustion and Enhances PD1 Blockade Therapy in Melanoma-Bearing Mice.

Darong Chen, Sisi Feng, Zhaolong Chen, Zhisheng Weng, Shu Zhang, Junjin Lin, Zili Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Darong ChenDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350004, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0009-0006-5579-3169
Sisi FengDepartment of Pathology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350004, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0000-0002-4472-1905
Zhaolong ChenDepartment of Internal Medicine, Luoyuan County General Hospital, Fuzhou, 350600, Fujian, China.
Zhisheng WengDepartment of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350004, Fujian, China, fjmu.edu.cn.
Shu ZhangDepartment of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350004, Fujian, China, fjmu.edu.cn.
Junjin LinPublic Technology Service Center, Fujian Medical University, Fuzhou, 350122, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0009-0008-7452-6319
Zili WangDepartment of Oncology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350004, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0000-0003-1674-3397

Funding

Natural Science Foundation of Fujian Province 2022J01223Natural Science Foundation of Fujian Province 2023J01314Natural Science Foundation of Fujian Province 2024J01570Startup Fund for Scientific Research of Fujian Medical University 2022QH1089
6 · The paper itself

Abstract

Continuous antigen exposure initiates the developmental process of CD8+ T cell exhaustion, accompanied by a gradual increase in the expression of inhibitory receptors (IRs). Our previous study conceptualized T cell exhaustion as an over-activation status induced by chronic antigen stimuli. To intervene in the developmental process of CD8+ T cell exhaustion, we adjusted the over-activation status by intermittently blocking T cell activation signals with tacrolimus, a T cell activation inhibitor. Melanoma-bearing mice received intermittent tacrolimus (IT) and/or programmed cell death 1 (PD1) blockade antibody. Exhaustion phenotype of CD8+ tumor-infiltrating lymphocytes (CD8+TILs) was detected by flow cytometry. The expression levels of IRs (PD1 and CD223), as well as memory markers (Ly108 and CD127), were utilized to demarcate the extent of CD8+TILs exhaustion. Then, tyrosinase-related protein 2 peptide (Trp2

Indexed as

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMelanomaProgrammed Cell Death 1 ReceptorTacrolimusAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansLymphocyte ActivationMiceMice, Inbred C57BLT-Cell ExhaustionImmune Checkpoint InhibitorsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorTacrolimusover-activationPD1 blockadetacrolimuT cell exhaustion

Identifiers

PMID41811893
PMCPMC13140372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.